Evidence map›Paper›PMID 22321016›Full record

ArticleOmics : a journal of integrative biology

Cognitive disorders in mice: cytokine signaling pathways as therapeutic targets.

Alexander Pukhalsky, Galina Shmarina, Vladimir Alioshkin

Open access · greenAbstract read
In one paragraph

Article in Omics : a journal of integrative biology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Alexander PukhalskyResearch Centre for Medical Genetics, Moscow, Russia. osugariver@yahoo.com
Galina Shmarina
Vladimir Alioshkin
Research Centre for Medical Genetics · RUGabrichevsky Institute of Epidemiology and Microbiology · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Surplus accumulation of regulatory T cells (Tregs) is known to be at the bottom of many morbid conditions, among them being neuropsychiatric diseases. In particular, Tregs may inhibit Th1 cells, including brain autoimmune lymphocytes, controlling the local microglial response and brain tissue homeostasis. The present study was undertaken in an attempt to suggest a novel approach for the treatment of maladaptation to mental stress associated with excessive Treg accumulation. Recently it was shown that alkylating drugs (ADs), such as melphalan and cyclophosphamide (Cy) in the dose 100-fold lower than cytostatic one are capable to disturb signal transduction by IL-2R. In this study we demonstrated that IL-2R is not a unique receptor, which may be blocked with ADs. Similar effect has been shown for two other surface receptors: TNFR and Fas. Molecular mechanisms of the receptor blockage were investigated on the model of TNF signaling. Study of NF-κB activity in nuclear extracts showed that alkylating agents act at the level of surface receptor or of the receptor platform. It was also shown that ADs administration in ultralow doses results in selective elimination of Tregs. In this study we used a new laboratory model of Treg accumulation in mice. Such Treg accumulation was associated with cognitive and behavioral abnormalities, which may be prevented by Cy administration.

Indexed as

CyclophosphamideAnimalsAntineoplastic Agents, AlkylatingBehavior, AnimalCognition DisordersCytokinesImmunosuppressive AgentsMaleMaze LearningMelphalanMiceMice, Inbred BALB CNF-kappa BReceptors, Interleukin-2Signal TransductionStress, PsychologicalAntineoplastic Agents, AlkylatingCyclophosphamideCytokinesImmunosuppressive AgentsMelphalanNF-kappa BReceptors, Interleukin-2

Identifiers

PMID22321016
PMCPMC3275797
OpenAlexW1964760549

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.